DuPont has introduced DuPont™ AmberChrom™ XT20 SL and XT30 SL chromatography resins designed to simplify and accelerate the purification process of oligonucleotide and peptide therapeutics. These new slurried resins eliminate the need for a resin hydration step before column packing, reducing preparation time and capital investment for manufacturers. This innovation supports the growing demand for efficient downstream processing in producing targeted medicines for genetic, metabolic, and cancer-related diseases. The XT20 SL resin offers high resolution for precise separations, while the XT30 SL resin provides faster flow rates, enhancing flexibility in manufacturing workflows.
DuPont has introduced a comprehensive Direct Lithium Extraction (DLE) portfolio featuring over 20 products, including sorbents, membranes, and ion exchange resins, designed to enhance lithium recovery from various brine compositions. This integrated ...
DuPont will release its financial results for the second quarter of 2026 on August 4 at 6:00 a.m. ET. The company will also hold a live conference call at 8:00 a.m. ET the same day, accessible via webcast and phone. Investors can find the earnings re...
